he headline for 2026 is not that AI is getting smarter. It is that expectations are becoming defined. On January 14, 2026, the US FDA and the European Medicines Agency (EMA) published joint Guiding Principles for Good AI Practice in Drug Development. While legally nonbinding, these principles provide a window into the agencies’ current thinking and a benchmark during regulatory review. It is a signal of regulatory alignment on what “good” looks like when AI supports evidence across the drug development lifecycle, including clinical trials and safety monitoring.

The principles are not a new rulebook. They are a reference point for how to apply AI inside regulated processes. Guidelines are technology-neutral but operationally specific: define the context of use, apply risk-based controls, govern data and documentation, and manage the system across its lifecycle so that oversight remains intact.

The focus on whether AI can be used has now shifted to prioritizing continued oversight that guarantees that AI is implemented in a responsible and controlled way.

Shifting from Experimentation to Consistency and Accountability

Over the past 18–24 months, many life sciences organizations have explored AI in “text-heavy” and assistive use cases: summarizing long documents, classifying content, extracting data points, and drafting internal or external text. This is a logical starting point because it is fast to pilot and easy to demonstrate value.

The harder step? What comes next.

As soon as AI output starts to influence regulated evidence, decisions, or actions, “it appears to work” is no longer the standard. The standard is now evolving to become repeatable with oversight: consistent use in context, clear accountability with a human in the loop, and a record that holds up to audit scrutiny over time. That is what the EMA–FDA principles bring into sharper focus.

Context of Use Becomes Essential for “Good” AI Practice

The most consequential phrase in the regulators’ framing is “context of use.” AI is not evaluated in the abstract. It is evaluated in the context of what it is intended to do, what it influences, and what risk it introduces.

A drafting assistant used to summarize internal notes is one thing. AI that uses the same summarization method to prioritize safety case review, flag potential signals, or initiate steps in trial operations is another. The same underlying technique can move from low impact to high impact simply by where it sits in the process and how its output is used.

For example, using AI to identify trends in past health authority questions is a lower impact context of use for regulatory affairs. Building on this use case, using AI to research and then assist in building a response heightens impact and risk. And creating a final response with no subsequent human review in the process becomes an extremely high impact context of use.

This context matters because it changes what “good practice” requires in the real world. While FDA and EMA now require a structured, risk‑based credibility assessment for AI in drug development, neither agency has issued a formal risk‑classification system for specific AI use cases. But when the context of use is higher risk, the surrounding expectations should shift with it: clearer controls, stronger documentation, explicit human oversight, and more disciplined change management.

The practical implication is that AI programs will increasingly need an inventory of use cases mapped to risk, with defined boundaries and a shared understanding of accountability.

AI Delivered Natively Within Workflows Strengthens Governance

The guiding principles are technology-neutral, but they are not neutral about execution. In practice, this broadens attention beyond the model itself to the surrounding controls and documentation: data provenance, versioning, how outputs are reviewed and used, and what changed over time.

This is where a strategic design choice becomes critical: whether AI sits outside the regulated workflow as a separate tool, or whether it is natively part of workflows inside the systems where regulated work actually happens.

When AI output is delivered as part of a regulated workflow, it may trigger additional validation obligations under the FDA’s electronic records and systems expectations, but these workflows can inherit what regulated environments already require: role-based permissions, standardized steps, controlled handoffs, and audit trails by design.

When AI sits outside, teams often end up reconstructing context and controls after the fact, copying information across tools, reconciling versions, and rebuilding the “story of the record” during reviews and inspections. This is manageable in a pilot. It is fragile at scale.

This “native by design” direction is also where industry product strategy is heading. For critical processes such as eTMF intake, health authority correspondence processing, and medical, legal, and regulatory review of promotional materials, delivering AI that natively works with operational systems of record better aligns structurally with governed data, auditability, and repeatable oversight, rather than treating AI as a separate overlay.

Lifecycle Management as an Operational Discipline

Lifecycle management can sound abstract until you map it to how AI behaves in production.

Newer foundational models are released. Prompts derived from agent objectives and instructions evolve. Knowledge sources and transactional data change. Any of those changes can subtly alter AI outputs in ways that matter in a regulated context. The FDA/EMA Joint Principles’ emphasis on risk-based performance assessment and lifecycle management is, in practice, a reminder that “set it and forget it” is not an option after AI influences regulated work.

Both the FDA and EMA have now codified requirements for AI lifecycle management. FDA’s Predetermined Change Control Plan establishes expectations for managing model updates and AI drift, and the EU AI Act together with Annex 22 requires post‑market monitoring, drift detection, and change-control procedures for high‑risk AI systems.

So, what does “lifecycle management” mean in operational terms?

• Version control that is audit-relevant not only for code and models, but also for prompts, agent instructions, templates, and reference material that influences outputs.
• Defined monitoring and drift triggers that define what you monitor, how often, and what constitutes meaningful change.
• Change control proportional to risk when a change requires documentation, review, requalification, or rollback.
• Clear accountability when AI output is accepted, overridden, or escalated so that responsibility does not evaporate into “the algorithm said so.”

These are operating model disciplines. They are not optional add-ons delegated to a data science team. They sit at the intersection of quality, business process ownership, and technology, which is exactly where regulated execution already lives.

Global Regulations Converging on Responsible Use

The FDA-EMA principles arrive as part of a wider regulatory pattern that reinforces the same underlying message: Trustworthy technology depends on trustworthy execution.

The European Commission’s timeline for the EU AI Act makes governance expectations increasingly concrete. While applicability of the Act varies by article and chapter, the main application date of the Act arrived on August 2, 2026, alongside earlier milestones for prohibited practices and AI literacy (from February 2, 2026) and general-purpose AI obligations (from August 2, 2025).

In the US, FDA’s October 2024 Q&A guidance on electronic systems, electronic records, and electronic signatures in clinical investigations clarifies what it means for electronic records and systems to be trustworthy and reliable. It is not AI guidance, but it becomes directly relevant when AI output is part of evidence generation. If AI influences evidence and decisions, the integrity of the electronic record and the system that produced it becomes more central, not less.

None of the above suggests that regulators want to slow innovation. The joint principles are explicitly framed to enable responsible use. The operational bar is rising in a way that rewards organizations which make oversight practical, repeatable, and scalable.

How Leaders Can Design a Framework for AI at Scale

The practical response is not to slow down AI adoption. It is to operationalize it, so each new use case does not trigger a fresh governance debate.

For most organizations, the near-term opportunity is to use the FDA-EMA principles as a design requirement for the AI operating environment, even while product capabilities across clinical, regulatory, and safety continue to mature across the market. This means doing the foundational work to move from isolated AI applications to a governed capability in a regulated execution environment. That involves defining contexts of use, mapping them to risk, standardizing what “essential information” looks like for oversight, and putting lifecycle controls around what changes and when.

This is also the moment to push vendors for specificity. The question is not Does it do AI? but Where is AI in the workflow, what record does it produce, what is versioned, what is auditable, what is monitored, and what changes under change control? This will inform how tools meet existing regulations for validated systems and new expectations for good AI practice. The more AI works natively with the systems that already manage roles, permissions, workflows, and audit trails, the easier it becomes to scale responsibly over time without rebuilding evidence and oversight from scratch.

Raising the Bar for Operational AI

The FDA-EMA principles mark a significant shift from viewing AI as a separate tool to one that natively works within controlled workflows to support evidence generation and monitoring. This means that decisions can be reviewed and traced with clear oversight and transparent change management.

Success will rely on enabling AI within the regulated foundation of operations, turning governance and oversight from compliance requirements into an operational advantage.